Last reviewed · How we verify
Rebif New Formulation Non Titrated
Rebif New Formulation Non Titrated is an interferon beta-1a formulation used to treat multiple sclerosis.
Rebif New Formulation Non Titrated is an interferon beta-1a formulation used to treat multiple sclerosis. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | Rebif New Formulation Non Titrated |
|---|---|
| Sponsor | EMD Serono |
| Drug class | Interferon |
| Target | IFNAR |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to reduce inflammation in the central nervous system, thereby reducing the frequency and severity of MS relapses. Interferon beta-1a has been shown to slow the progression of disability in patients with relapsing forms of MS. However, its exact mechanism of action is not fully understood and may involve multiple pathways.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Flu-like symptoms
- Injection site reactions
- Fatigue
- Headache
- Depression
- Anxiety
- Liver enzyme elevations
- Thrombocytopenia
- Leukopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rebif New Formulation Non Titrated CI brief — competitive landscape report
- Rebif New Formulation Non Titrated updates RSS · CI watch RSS
- EMD Serono portfolio CI